BMF-219 is currently supplied as 25 and 100 mg strength capsules for oral administration.

Preclinical data of BMF-219 show sustained potent abrogation of menin-dependent oncogenic signaling in multiple cancers.

Menin, a protein involved in transcriptional regulation, impacting cell cycle control, apoptosis, and DNA damage repair, plays a direct role in oncogenic signaling in multiple cancers.

Approximately 20 clinical sites in the United States.

BMF-219 demonstrates a strong anti-proliferative effect on various menin-dependent acute myeloid leukemia (AML) cell lines, DLBCL cell lines representing Double/Triple Hit Lymphoma (DHL/THL), Double Expressor Lymphoma (DEL), and MM cell lines harboring diverse mutational backgrounds.

BMF-219 also exhibits high potency ex vivo in patient samples from MLL-rearranged and NPM1-mutant AML, THL and MYC-amplified DLBCL, and bone marrow mononuclear cells from treatment-naïve and R/R MM.

BMF-219 is currently supplied as 25 and 100 mg strength capsules for oral administration.